A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations

Trial Profile

A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 29 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Feb 2015 Planned End Date changed from 1 Dec 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
    • 05 Feb 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top